Table 1 Demographics and clinical characteristics of CPM patients undergoing CRS and HIPEC

 Age, years

54.0 (24–78)

49 (24–72)

55 (30–78)

0.132

 Gender

1.000

  Male

39 (38.2%)

8 (40%)

31 (37.8%)

  Female

63 (61.8%)

12 (60%)

51 (62.2%)

 Race

0.004

  Chinese

85 (82.5%)

12 (60.0%)

73 (89.0%)

  Others

17 (17.5%)

8 (40.0%)

9 (11.0%)

 ECOG status

0.350

  0/1

94 (92.2%)

20 (100.0%)

74 (90.2%)

  2

8 (7.8%)

0 (0.0%)

8 (9.8%)

 T-stage (primary tumour)

0.502

  T1–2

3 (2.9%)

0 (0.0%)

3 (3.7%)

  T3–4

99 (97.1%)

20 (100%)

79 (96.3%)

 N-stage (primary tumour)

0.15

  N0–1

63 (61.8%)

11 (55%)

52 (63.4%)

  N2

31 (30.4%)

6 (30%)

25 (30.4%)

  Unknown

8 (7.8%)

3 (15%)

5 (6.2%)

 Tumour differentiation (primary tumour)

1.02

  Well

5 (5%)

1(5%)

4 (4.8%)

  Moderate

60 (58.8%)

10 (50%)

50 (61%)

  Poor

31 (30.4%)

7(35%)

24 (29.3%)

  Unknown

6 (5.8%)

2 (10%)

4 (4.9%)

 Histology (primary tumour)

0.51

  Adenocarcinoma

74 (72.5%)

13 (65.0%)

61 (74.5%)

  Mucinous

23 (22.5%)

6 (30.0%)

17 (20.7%)

  Signet ring cell

2 (2%)

0 (0.0%)

2 (2.4%)

  Mixed

2 (2%)

1 (5.0%)

1 (1.2%)

  Others

1 (1%)

0 (0.0%)

1 (1.2%)

 Sidedness of Tumour (primary tumour)

0.54

  Right

32 (31.4%)

7 (35%)

25 (30.5%)

  Left

51 (50%)

10 (50%)

41 (50%)

  Rectum

15 (14.7%)

1 (5%)

14 (17%)

  Unknown

4 (3.9%)

2 (10%)

2 (2.5%)

 Pre-operative CEA levels, mean (μG/l)

32.3

43.1 (1.1 - 501)

29.8 (0.5 – 441)

0.043

 PCI score, median (range)

7 (0–27)

9 (3–27)

5 (0–24)

0.12

 PCI score

0.11

  < 10

55 (54%)

10 (50%)

45 (54.9%)

  10–20

31 (30.3%)

4 (20%)

27 (32.9%)

  > 20

5 (5%)

3 (15%)

2 (3.8%)

  Unknown

11 (10.7%)

3 (15%)

8 (8.4%)

 CC-score

0.352

  CC0

101 (98.1%)

19 (95.0%)

82 (100%)

  CC1

1 (1.0%)

1 (5.0%)

0 (0.0%)